Needham & Company
-
UiPath and ManpowerGroup Deepen Strategic Partnership to Help Organizations find the Right Blend of People, Skills, and Automation
-
UiPath Inc. (PATH) PT Lowered to $40 at Needham & Company
-
UiPath to Present at the 24th Annual Needham Virtual Growth Conference
-
UiPath (PATH) Stock Down Despite Overall Q3 Beat, Analyst Upgrades to Buy on Valuation
-
UiPath Inc. (PATH) Customer Conference Feedback Implies Sharp Uptick in Cloud RPA Demand - Needham
-
UPDATE: Needham & Company Starts UiPath Inc. (PATH) at Buy
-
UiPath Announces Closing of Initial Public Offering
-
UiPath (PATH) IPO Opens 17% Higher
-
UiPath Inc. (PATH) Prices 23.89M Share IPO at $56/Sh
-
UiPath Announces Pricing of Initial Public Offering
-
Pre-Open Stock Movers 1/21: (HEB) (YRCW) (DOW) Higher; (AMRN) (PATH) (DB) Lower (more...)
-
Pre-Open Stock Movers 1/8: (PATH) (FRX) (MU) Higher; (TCS) (JCP) (TWTR) Lower (more...)
-
StreetInsider.com Pre-Open Movers 01/22: (ATNI) (BOX) (RIMM) Higher; (ARNA) (NUS) (FTNT) Lower (more...)
-
Needham & Company Maintains a 'Hold' on NuPathe (PATH); Continues Marching Forward
-
Needham & Company Maintains a 'Buy' on NuPathe (PATH); Zelrix Profile Continues to Grow Ahead of August FDA Action Date
-
Morning Movers 08/03: (CBM) (SIMG) (FIX) (GNET) Higher; (CBR) (KFRC) (EXAM) (KRA) Lower
-
Needham & Company Initiates Coverage on NuPathe (PATH) with a 'Buy'; Zelrix Poised To Emerge As Differentiated Treatment Option In Migraine
-
NuPathe (PATH) IPO Trades Flat
-
NuPathe (PATH) Sees IPO Price at $10/Share
-
NuPathe (PATH) Sees IPO Price of $14 - $16/Share
-
NuPathe Inc. (PATH) Files $86.25M IPO